Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

KalVista Pharmaceuticals (KALV) Current Leases: 2017-2024

Historic Current Leases for KalVista Pharmaceuticals (KALV) over the last 4 years, with Dec 2024 value amounting to $1.5 million.

  • KalVista Pharmaceuticals' Current Leases was N/A to $1.5 million in Q4 2024 from the same period last year, while for Dec 2024 it was $1.5 million, marking a year-over-year change of. This contributed to the annual value of $1.3 million for FY2024, which is N/A change from last year.
  • Per KalVista Pharmaceuticals' latest filing, its Current Leases stood at $1.5 million for Q4 2024, which was down 5.53% from $1.5 million recorded in Q4 2024.
  • In the past 5 years, KalVista Pharmaceuticals' Current Leases ranged from a high of $1.5 million in Q4 2024 and a low of $422,000 during Q4 2020.
  • Its 2-year average for Current Leases is $1.3 million, with a median of $1.3 million in 2024.
  • Within the past 5 years, the most significant YoY rise in KalVista Pharmaceuticals' Current Leases was 988.89% (2020), while the steepest drop was 29.90% (2020).
  • Over the past 4 years, KalVista Pharmaceuticals' Current Leases (Quarterly) stood at $422,000 in 2020, then remained steady at $592,000 in 2021, then reached $1.1 million in 2023, then surged by 33.89% to $1.5 million in 2024.
  • Its Current Leases was $1.5 million in Q4 2024, compared to $1.5 million in Q4 2024 and $1.3 million in Q3 2024.